Skip To Main Content
Ahn MJ on Muck Rack

Ahn MJ

As seen in: Wiley Online Library, Oxford University Press (OUP)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Ahn MJ’s profile

Articles by Ahn MJ

Tarlatamab plus anti-PD‐L1 as first‐line maintenance for ES‐SCLC demonstrates promising results

|
By Leah Lawrence, Paulson KG, Lau SCM, Ahn MJ
| Wiley Online Library Verified
The combination of tarlatamab plus a PD-L1 inhibitor as maintenance therapy after first-line chemoimmunotherapy demonstrated a manageable safety profile and promising activity in patients with extensive-stage small cell lung cancer (ES-SCLC).
Open in Who Shared Issue with article?

Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

|
By Lee DH, Kim HR, Ahn MJ
| nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (160) Issue with article?

Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA - PubMed

|
By Byoung Chul Cho, Gray JE, Ahn MJ, Oxnard GR
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (366) Issue with article?

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer

|
By Riely GJ, Ahn MJ, Smit EF, Ramalingam SS
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (624) Issue with article?

Durvalumab in Combination with Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study

|
By Byoung Chul Cho, Byoung Yong Shim, Ahn MJ, Cho BC
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (555) Issue with article?

The prognostic value of radiomic features from pre- and post-treatment 18F-FDG PET imaging in patients with nasopharyngeal carcinoma

|
By Kim SJ, Choi JY, Ahn MJ, Ahn YC
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (628) Issue with article?

Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

|
By Jung Ha, Ahn JS, Ahn MJ, Sun JM
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (607) Issue with article?

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer - PubMed

|
By Ahn MJ, Poddubskaya EV, Cho BC, Han JY
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (552) Issue with article?

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

|
By Lee JK, Lee SH, Ahn MJ
| Oxford University Press (OUP)
This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or recurrent NSCLC with a RET rearrangement, which was confirmed by fluorescence in situ hybridization, had progressive disease against platinum-based doublet chemotherapy, and had a performance status of 0–2. The primary endpoint was the objective response rate. A total of 18 patients were enrolled in this study between July 2013 and October 2015.
Open in Who Shared Issue with article?
Show More